Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors

Summary Background Aurora A kinase (AurA) overexpression likely contributes to tumorigenesis and therefore represents an attractive target for cancer therapeutics. This phase 1 study aimed to determine the safety, pharmacokinetics, and antitumor activity of LY3295668 erbumine, an AurA inhibitor, in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2021-08, Vol.39 (4), p.1001-1010
Hauptverfasser:	Chu, Quincy Siu-chung, Bouganim, Nathaniel, Fortier, Caroline, Zaknoen, Sara, Stille, John R., Kremer, Jill D., Yuen, Eunice, Hui, Yu-Hua, de la Peña, Amparo, Lithio, Andrew, Smith, Patricia S., Batist, Gerald
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adverse events Aged Alopecia Anorexia Anticancer properties Antitumor activity Aurora kinase Aurora Kinase A - antagonists & inhibitors Constipation Cornea Diarrhea Disease control Dosage Dose-Response Relationship, Drug Enzyme inhibitors Female Humans Kinases Male Maximum Tolerated Dose Medicine Medicine & Public Health Metastases Metastasis Middle Aged Mucositis Nausea Neoplasms - drug therapy Neoplasms - pathology Oncology Patients Pharmacokinetics Pharmacology Pharmacology/Toxicology Phase I Studies Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - pharmacokinetics Safety Schedules Solid tumors Toxicity Treatment Outcome Tumorigenesis Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!